Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
MEZLIN (mezlocillin sodium monohydrate) is an injectable antibiotic belonging to the penicillin class, used to treat bacterial infections. It is administered parenterally and represents a legacy anti-infective product approved in 1981. The drug targets susceptible gram-negative and gram-positive organisms across multiple infection types.
As a legacy antibiotic with LOE approaching, the commercial team is likely focused on defending existing market share in hospitals rather than growth, suggesting smaller brand team and defensive positioning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on MEZLIN offers limited career growth potential given its LOE-approaching status and zero linked job openings. The role is suited for professionals seeking stable, low-profile positions in hospital-based sales or antimicrobial stewardship, rather than high-visibility brand leadership.
Worked on MEZLIN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.